A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity

Gut

Volumn 62, Issue 4, 2013, Pages 594-605

  Oancea, Iulia ^a,b   Png, Chin Wen ^a   Das, Indrajit ^a   Lourie, Rohan ^a,c   Winkler, Ingrid G ^a   Eri, Rajaraman ^a   Subramaniam, Nathan ^d   Jinnah, H A ^e   McWhinney, Brett C ^f   Levesque, Jean Pierre ^a   McGuckin, Michael A ^a,b   Duley, John A ^a,b,c   Florin, Timothy H J ^a,b,c  

^a MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c MATER HOSPITAL   (Australia)

^d QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Queensland Pathology Services   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; PADGEM PROTEIN; THIOGUANOSINE; TIOGUANINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; BLOOD TOXICITY; COLITIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; GENE; GENE MUTATION; HEPATITIS; HISTOPATHOLOGY; IMMUNE DEFICIENCY; IMMUNOCHEMISTRY; LEUKOCYTE FUNCTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MALE; MOUSE; MUC2 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SINGLE NUCLEOTIDE POLYMORPHISM; SPLIT DOSING; SURVIVAL RATE; TREATMENT DURATION; VASCULAR ENDOTHELIUM;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATIC VENO-OCCLUSIVE DISEASE; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED C57BL; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; THIOGUANINE;

EID: 84874657628     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302274     Document Type: Article

References (55)

1. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit 2005;27:647-54. (Pubitemid 41437645)
2. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45. (Pubitemid 36519931)
3. Gisbert JP, Nino P, Cara C, et al. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008;28:228-38. (Pubitemid 351861969)
4. Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011;106:981-7.
5. Bardhan KD, Simmonds N, Royston C, et al. A United Kingdom inflammatory bowel disease database: making the effort worthwhile. J Crohns Colitis 2010;4:405-12.
6. Colombel J, Sandborn W, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95.
7. Ansari A, Arenas M, Greenfield S, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:973-83.
8. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13. (Pubitemid 30171620)
9. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15. (Pubitemid 34267273)
10. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005;22:441-6. (Pubitemid 41248111)
11. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:640-7.
12. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003;98:1058-63. (Pubitemid 36733767)
13. Cheung TK, Florin TH. 6-Thioguanine: a new old drug to procure remission in inflammatory bowel disease. Intern Med J 2003;33:44-6. (Pubitemid 36241573)
14. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003;18:401-8. (Pubitemid 37070238)
15. Derijks LJ, De Jong DJ, Gilissen LP, et al. 6-Thioguanine seems promising in azathioprine-or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003;15:63-7. (Pubitemid 36135664)
16. Stork LC, Matloub Y, Broxson E, et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood 2010;115:2740-8.
17. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125:298-303. (Pubitemid 36929408)
18. Wanless I. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2, 500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990;11:787-97. (Pubitemid 20191384)
19. Ziol M, Poirel H, Kountchou GN, et al. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol 2004;35:1241-51. (Pubitemid 39361648)
20. Rubbia-Brandt L, Lauwers G, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin- associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Clin Liver Dis 2010;14:651-68.
21. De Leve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology 1999;29:1779-91. (Pubitemid 29247052)
22. Deleve LD, Wang X, Tsai J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 2003;125:882-90. (Pubitemid 37070704)
23. Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Thomas ED, Blume KG, Forman SJ, eds. Haematopoietic Stem Cell Transplantation. Cambridge, MA: Blackwell Publishing, 1999:627-45.
24. Heazlewood CK, Cook MC, Eri R, et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 2008;5:e54.
25. Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010;105:2420-8.
26. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998;44:551-5. (Pubitemid 28141350)
27. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-8.
28. Gibney MJ, Lanham-New SA, Cassidy A. Introduction to Human Nutrition. Oxford, UK: Blackwell Publishing, 2009:45.
29. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 2005;43:303-9. (Pubitemid 40956884)
30. De Boer NK, Derijks LJ, Gilissen LP, et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 2005;11:5540-4.
31. Ansari A, Elliott T, Fong F, et al. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm Bowel Dis 2008;14:1399-405.
32. Valentijn KM, Sadler JE, Valentijn JA, et al. Functional architecture of Weibel-Palade bodies. Blood 2011;117:5033-43.
33. Subramaniam M, Koedam J, Wagner D. Divergent fates of P-and E-selectins after their expression on the plasma membrane. Mol Biol Cell 1993;4:791-801. (Pubitemid 23274240)
34. Kunkel EJ, Ley K. Distinct phenotype of E-selectin-deficient mice. E-selectin is required for slow leukocyte rolling in vivo. Circ Res 1996;79:1196-204. (Pubitemid 26404152)
35. Frenette PS, Wagner DD. Insights into selectin function from knockout mice. Thromb Haemost 1997;78:60-4. (Pubitemid 27289216)
36. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008;111:5271-81.
37. Eri R, Adams R, Tran T, et al. An intestinal epithelial defect conferring ER stress results in inflammation involving both innate and adaptive immunity. Mucosal Immunol 2011;4:354-64.
38. Gilissen LP, Derijks LJ, Driessen A, et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig Liver Dis 2007;39:156-9. (Pubitemid 46117931)
39. Van Asseldonk DP, Jharap B, Kuik DJ, et al. Prolonged thioguanine therapy is well tolerated and safe in the treatment of ulcerative colitis. Dig Liver Dis 2011;43:110-15.
40. Russmann S, Zimmermann A, Krahenbuhl S, et al. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001;13:287-90. (Pubitemid 32205420)
41. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007;56:1404-9. (Pubitemid 47517834)
42. Vora A, Mitchell CD, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006;368:1339-48. (Pubitemid 44528747)
43. Shann F. Drug Doses. Melbourne, Victoria: Royal Children's Hospital, Collective Publishing, 2006:3-7.
44. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34:738-46.
45. Krynetskaia NF, Krynetsky EY, Evans WE. Human RnaseH-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxy-guanosine incorporation into DNA. Mol Pharmacol 1999;56:841-8. (Pubitemid 29491188)
46. Arenas M, Simpson G, Lewis CM, et al. Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin Chem 2005;51:2371-4. (Pubitemid 41692587)
47. Van Os EC, Zins BJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996;39:63-8. (Pubitemid 26239107)
48. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983;308:1005-9. (Pubitemid 13118706)
49. Odlind B, Hartvig P, Lindstrom B, et al. Serum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine in uremic patients. Int J Immunopharmacol 1986;8:1-11. (Pubitemid 16170390)
50. Brunschede H, Krooth RS. Studies on the xanthine oxidase activity of mammalian cells. Biochem Genet 1973;8:341-50.
51. Kurowsky V, Iven H. Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice. Cancer Chemother Pharmacol 1991;28:7-14.
52. Hampton A. Reactions of ribonucleotide derivatives of purine analogues at the catalytic site of inosine 5'-phosphate dehydrogenase. J Biol Chem 1963;238:3068-74.
53. Lancaster DL, Patel N, Lennard L, et al. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br J Clin Pharmacol 2001;51:531-9. (Pubitemid 32862742)
54. Lennard L, Rees CA, Lilleyman JS, et al. Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1983;16:359-63. (Pubitemid 13015758)
55. Hernandez JS, Van Loon JA, Otterness DM, et al. Mouse thiopurine methyltransferase pharmacogenetics: correlation of immunoreactive protein and enzymatic activity. J Pharmacol Exp Ther 1990;252:568-73. (Pubitemid 20101867)